Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod in Children and Adolescents With Generalized Myasthenia Gravis (ADAPT Jr)
NCT04833894Phase 3Active, not recruiting
- Sponsor
- argenx
- Start
- Oct 2021
- Primary completion
- Mar 2027
- Countries
- 12
01
Overview
A Phase 3 trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by argenx. Started Oct 2021; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT04833894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04833894.